Angina I

Question 1

Dobutamine

Answer 1

Directly stimulates beta-1 receptors, increases contractility and heart rate. Can be used instead of stress test.

Question 2

Adenosine or dipyridamole

Answer 2

Coronary vasodilators. They inhibit cellular uptake and degradation of adenosine. Only works if coronary arteries are healthy.

Question 3

Ticlopidine

Answer 3

Inhibits ADP-induced platelet aggregation. Decreases fibrinogen and increases red cell deformability, reducing blood viscocity. SIDE EFFECTS: induces neutropenia and rarely TTP.

Question 4

Clopidogrel

Answer 4

Inhibits ADP-induced platelet aggregation. Has greater antithrombotic effect than ticlopidine and aspirin. Increased bleeding risk.

Question 5

Prasugrel

Answer 5

Irreversibly binds to P2Y12 receptor. Approved for use for those who have received a stent. Potent antiplatelet agent, but increased bleeding overrides its benefits.

Limited to: 60kg in weight, no history of stroke or TIA.

Question 6

Ticagrelor

Answer 6

Reversible blocker of ADP.

Question 7

Dipyridamole

Answer 7

Increases intracellular platelet cyclic adenosine monophosphate. Inhibits phosphodiesterase, activates adenylate cyclase and inhibits uptake of adenosine from vascular endothelium and RBCs. Limited because it vasodilates coronary arteries can enhance exercise induced ischemia.

Question 8

Cilostazol

Answer 8

Inhibits phosphodiesterase, increasing cAMP levels, resulting in inhibition platelet aggregation. Also causes vasodilation, increasing mortality in heart failure patients.

Question 9

Directly stimulates beta-1 receptors, increases contractility and heart rate. Can be used instead of stress test.

Answer 9

Dobutamine

Question 10

Coronary vasodilators. They inhibit cellular uptake and degradation of adenosine. Only works if coronary arteries are healthy.

Answer 10

Adenosine or dipyridamole

Question 11

Inhibits ADP-induced platelet aggregation. Decreases fibrinogen and increases red cell deformability, reducing blood viscocity. SIDE EFFECTS: induces neutropenia and rarely TTP.

Answer 11

Ticlopidine

Question 12

Inhibits ADP-induced platelet aggregation. Has greater antithrombotic effect than ticlopidine and aspirin. Increased bleeding risk.

Answer 12

Clopidogrel

Question 13

Irreversibly binds to P2Y12 receptor. Approved for use for those who have received a stent. Potent antiplatelet agent, but increased bleeding overrides its benefits.

Limited to: 60kg in weight, no history of stroke or TIA.

Answer 13

Prasugrel

Question 14

Reversible blocker of ADP.

Answer 14

Ticagrelor

Question 15

Increases intracellular platelet cyclic adenosine monophosphate. Inhibits phosphodiesterase, activates adenylate cyclase and inhibits uptake of adenosine from vascular endothelium and RBCs. Limited because it vasodilates coronary arteries can enhance exercise induced ischemia.

Answer 15

Dipyridamole

Question 16

Inhibits phosphodiesterase, increasing cAMP levels, resulting in inhibition platelet aggregation. Also causes vasodilation, increasing mortality in heart failure patients.

Answer 16

Cilostazol